METABOLIC MARKERS OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ABDOMINAL OBESITY

Objective: Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity and metabolic syndrome (MS). Liver biopsy can verify the histological form of NAFLD. The aim of the study was to evaluate the relationship between histological indicators of liver damage and metabolic parameters....

Full description

Bibliographic Details
Main Authors: Ksenya Komshilova, Natalya Mazurina, Ekaterina Trosina, Teona Shvangiradze, Pavel Bogomolov, Galina Melnichenko, Ivan Dedov
Format: Article
Language:English
Published: Bulgarian Association of Young Surgeons 2018-10-01
Series:International Journal of Surgery and Medicine
Subjects:
Online Access:http://www.ejos.org/index.php?fulltxt=357
id doaj-57f699fe99a94e1da174a01e0250c2bf
record_format Article
spelling doaj-57f699fe99a94e1da174a01e0250c2bf2021-04-03T16:27:17ZengBulgarian Association of Young SurgeonsInternational Journal of Surgery and Medicine2367-699X2367-699X2018-10-0144http://dx.doi.org/10.5455/ijsm.Risk-factors-in-various-forms-of-NAFLDMETABOLIC MARKERS OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ABDOMINAL OBESITYKsenya KomshilovaNatalya MazurinaEkaterina TrosinaTeona ShvangiradzePavel BogomolovGalina MelnichenkoIvan DedovObjective: Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity and metabolic syndrome (MS). Liver biopsy can verify the histological form of NAFLD. The aim of the study was to evaluate the relationship between histological indicators of liver damage and metabolic parameters. Material and methods: 80 patients, median age 45 [41.5; 47.5], with abdominal obesity and US signs of NAFLD were included in the study. All patients underwent percutaneous liver biopsy. Glucose levels during OGTT, total cholesterol, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglycerides (TG), ALT, and AST were measured. Fasting insulin, serum adiponectin, C-reactive protein (CRP) and active plasminogen antigen activator inhibitor-1 (PAI-1) were determined. Results: NAFLD was confirmed in 77 patients (96.3%), NASH – in 64 cases (80%), steatosis - in 11 cases (13.8%). In patients with steatosis, 72.7% had dyslipidemia, 63.6% had impaired glucose metabolism, 63.6% had insulin resistance (IR); with NASH – in 93.8%, 78.1% and 100%, respectively. Adiponectin level correlated negatively with IR indicators: HOMA-IR (r = - 0.45; p = 0.023) and fasting insulin (r = - 0.35; p = 0.024). NASH patients had significantly higher levels of CRP than those with steatosis: 3.8 [2.1; 6.7] mg/L vs 1,1 [1.0; 1.7] mg/L, (p <0.0001). PAI-1 activity correlated positively with anthropometric parameters, IR, the level of CRP, and negatively with adiponectin concentration. Conclusion: Metabolic disorders in patients with NAFLD are dependent upon the severity of the liver damage and the morphological stage of the disease.http://www.ejos.org/index.php?fulltxt=357nonalcoholic fatty liver diseaseliver biopsyabdominal obesitycardiovascular risk factorstype 2 diabetes mellitus risk factors
collection DOAJ
language English
format Article
sources DOAJ
author Ksenya Komshilova
Natalya Mazurina
Ekaterina Trosina
Teona Shvangiradze
Pavel Bogomolov
Galina Melnichenko
Ivan Dedov
spellingShingle Ksenya Komshilova
Natalya Mazurina
Ekaterina Trosina
Teona Shvangiradze
Pavel Bogomolov
Galina Melnichenko
Ivan Dedov
METABOLIC MARKERS OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ABDOMINAL OBESITY
International Journal of Surgery and Medicine
nonalcoholic fatty liver disease
liver biopsy
abdominal obesity
cardiovascular risk factors
type 2 diabetes mellitus risk factors
author_facet Ksenya Komshilova
Natalya Mazurina
Ekaterina Trosina
Teona Shvangiradze
Pavel Bogomolov
Galina Melnichenko
Ivan Dedov
author_sort Ksenya Komshilova
title METABOLIC MARKERS OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ABDOMINAL OBESITY
title_short METABOLIC MARKERS OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ABDOMINAL OBESITY
title_full METABOLIC MARKERS OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ABDOMINAL OBESITY
title_fullStr METABOLIC MARKERS OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ABDOMINAL OBESITY
title_full_unstemmed METABOLIC MARKERS OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ABDOMINAL OBESITY
title_sort metabolic markers of cardiovascular disease and type 2 diabetes mellitus in various clinical and morphological forms of nonalcoholic fatty liver disease in patients with abdominal obesity
publisher Bulgarian Association of Young Surgeons
series International Journal of Surgery and Medicine
issn 2367-699X
2367-699X
publishDate 2018-10-01
description Objective: Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity and metabolic syndrome (MS). Liver biopsy can verify the histological form of NAFLD. The aim of the study was to evaluate the relationship between histological indicators of liver damage and metabolic parameters. Material and methods: 80 patients, median age 45 [41.5; 47.5], with abdominal obesity and US signs of NAFLD were included in the study. All patients underwent percutaneous liver biopsy. Glucose levels during OGTT, total cholesterol, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglycerides (TG), ALT, and AST were measured. Fasting insulin, serum adiponectin, C-reactive protein (CRP) and active plasminogen antigen activator inhibitor-1 (PAI-1) were determined. Results: NAFLD was confirmed in 77 patients (96.3%), NASH – in 64 cases (80%), steatosis - in 11 cases (13.8%). In patients with steatosis, 72.7% had dyslipidemia, 63.6% had impaired glucose metabolism, 63.6% had insulin resistance (IR); with NASH – in 93.8%, 78.1% and 100%, respectively. Adiponectin level correlated negatively with IR indicators: HOMA-IR (r = - 0.45; p = 0.023) and fasting insulin (r = - 0.35; p = 0.024). NASH patients had significantly higher levels of CRP than those with steatosis: 3.8 [2.1; 6.7] mg/L vs 1,1 [1.0; 1.7] mg/L, (p <0.0001). PAI-1 activity correlated positively with anthropometric parameters, IR, the level of CRP, and negatively with adiponectin concentration. Conclusion: Metabolic disorders in patients with NAFLD are dependent upon the severity of the liver damage and the morphological stage of the disease.
topic nonalcoholic fatty liver disease
liver biopsy
abdominal obesity
cardiovascular risk factors
type 2 diabetes mellitus risk factors
url http://www.ejos.org/index.php?fulltxt=357
work_keys_str_mv AT ksenyakomshilova metabolicmarkersofcardiovasculardiseaseandtype2diabetesmellitusinvariousclinicalandmorphologicalformsofnonalcoholicfattyliverdiseaseinpatientswithabdominalobesity
AT natalyamazurina metabolicmarkersofcardiovasculardiseaseandtype2diabetesmellitusinvariousclinicalandmorphologicalformsofnonalcoholicfattyliverdiseaseinpatientswithabdominalobesity
AT ekaterinatrosina metabolicmarkersofcardiovasculardiseaseandtype2diabetesmellitusinvariousclinicalandmorphologicalformsofnonalcoholicfattyliverdiseaseinpatientswithabdominalobesity
AT teonashvangiradze metabolicmarkersofcardiovasculardiseaseandtype2diabetesmellitusinvariousclinicalandmorphologicalformsofnonalcoholicfattyliverdiseaseinpatientswithabdominalobesity
AT pavelbogomolov metabolicmarkersofcardiovasculardiseaseandtype2diabetesmellitusinvariousclinicalandmorphologicalformsofnonalcoholicfattyliverdiseaseinpatientswithabdominalobesity
AT galinamelnichenko metabolicmarkersofcardiovasculardiseaseandtype2diabetesmellitusinvariousclinicalandmorphologicalformsofnonalcoholicfattyliverdiseaseinpatientswithabdominalobesity
AT ivandedov metabolicmarkersofcardiovasculardiseaseandtype2diabetesmellitusinvariousclinicalandmorphologicalformsofnonalcoholicfattyliverdiseaseinpatientswithabdominalobesity
_version_ 1721543815036141568